title: NCCN Task Force Report: Bone Health in Cancer Care.
abstract: Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting.
authors: Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, USA.
authors: Julie R
authors: JR
authors: Gralow
authors: J Sybil
authors: JS
authors: Biermann
authors: Azeez
authors: A
authors: Farooki
authors: Monica N
authors: MN
authors: Fornier
authors: Robert F
authors: RF
authors: Gagel
authors: Rashmi N
authors: RN
authors: Kumar
authors: Charles L
authors: CL
authors: Shapiro
authors: Andrew
authors: A
authors: Shields
authors: Matthew R
authors: MR
authors: Smith
authors: Sandy
authors: S
authors: Srinivas
authors: Catherine H
authors: CH
authors: Van Poznak
mesh_terms: D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary / Q000628:therapy; D001943:Breast Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D003952:Diagnostic Imaging / Q000379:methods; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D018570:Risk Assessment
chemical_list: D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates